Actualités

Alliance Global lifted its SLS price target to $35 from $25, implying nearly 200% upside, and maintained a ‘Buy’ rating.

Opus Capital held 385,604 shares worth about $5.69 million after increasing its position by 11.3%.

An arbitrator recently dismissed Sellas’ claims against 3D Medicines and ordered about $1 million in legal-cost payments.

Investors named Johnson & Johnson, Merck, Pfizer, AbbVie, Eli Lilly and Bristol Myers as possible bidders.

J&J’s fast-growing Inlexzo bladder-cancer franchise could make IBRX either strategically attractive or a direct rival.

CEO Angelos Stergiou said slower event accrual may signal a “highly effective active arm.”

SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the first quarter.

SELLAS Life Sciences (SLS) has surged 550% in the past year, driven by technical momentum and speculative trading. SLS currently has no revenue, with all products in development or clinical trials, making the stock highly speculative. Technical indicators are overwhelmingly bullish, but high short interest highlights significant risk. Sentiment is...

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the 10 Stocks Investors Are Chasing Right Now. SELLAS Life Sciences extended its winning streak to an 8th straight session on Monday to soar to a new record high, as investors resumed buying positions after hinting at a potential takeover. In intra-day trading, the stock rocketed […]

Sellas Life Sciences, BlackBerry, and Ouster rallied to 52-week highs on Monday as investors rotated into the companies amid positive catalysts.

Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.

SLS short interest climbed to nearly 33% of the float as of June 15, compared to 28.4% at the beginning of the year.

The company updated the severance agreements for three of its top executives, including the CEO.

CEO Angelos Stergiou said the trial's extended duration suggests patients are living longer than originally projected and said the company remains "very bullish."

Sellas believes GPS-treated AML patients could live longer than those receiving standard treatment, with a projected survival of about 12.6 months versus 8 months.

Sellas will participate Wednesday in TD Cowen’s Oncology Innovation Summit, marking the final major conference appearance ahead of the Regal data release.

Arm Holdings surged more than 15%, while Sellas Life Sciences rallied by over 18% and eBay climbed up 4% at close.

SELLAS Life Sciences Group, Inc. (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.